181 |
Betamethasone Sodium Phosphate 4 mg/ml Injection |
H02AB01162P3001XX |
B |
Pre-operative and in serious trauma or illness, shock, as adjunctive therapy in rheumatoid disorders, ocular, dermatologic and respiratory allergic and inflammatory states |
|
Usual intravenous doses are up to 9 mg/day of the sodium phosphate salt only. CHILD: IM: 0.5 - 7.7 mg base/m2/day divided every 6 - 12 hours. ADOLESCENT and ADULT, IM: 0.6 - 9 mg divided every 12 - 24 hours |
182 |
Bicalutamide 50 mg Tablet |
L02BB03000T1001XX |
A* |
Androgen deprivation therapy in advanced prostate cancer in combination with luteinising hormone-releasing hormone (LHRH) analogue therapy or surgical castration. |
|
50 mg once daily. (morning or evening), with or without food. Take on the same time each day. Adult: When used with gonadorelin analogue: Usual dose: 50 mg once daily. May be started with or at least 3 days before starting gonadorelin analogue therapy. |
183 |
Bimatoprost 0.01% ophthalmic solution |
S01EE03000D20-02XXX |
A* |
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta blockers). |
To be used as 2nd line |
One drop in the affected eye(s) once daily, administered in the evening. |
184 |
Bisacodyl 10 mg Suppository |
A06AB02000S2002XX |
C |
i) Constipation ii) Bowel preparation for radiological procedures and surgery |
|
i) ADULT and CHILD over 10 years: 10 mg, CHILD less than 10 years 5 mg insert rectally ii) ADULT 10-20 mg, CHILD over 4 years 5 mg the following morning before procedures insert rectally |
185 |
Bisacodyl 5 mg Suppository |
A06AB02000S2001XX |
C |
i) Constipation ii) Bowel preparation for radiological procedures and surgery |
|
i) ADULT and CHILD over 10 years: 10 mg, CHILD less than 10 years 5 mg insert rectally ii) ADULT 10-20 mg, CHILD over 4 years 5 mg the following morning before procedures insert rectally |
186 |
Bisacodyl 5 mg Tablet |
A06AB02000T1001XX |
C |
i) Constipation ii) Bowel preparation for radiological procedures and surgery |
|
i) ADULT and CHILD over 10 years 5-10 mg, CHILD 4-10 years 5 mg. To be taken at night for effect on the following morning ii) ADULT 10-20 mg the night before procedures, CHILD over 4 years 5 mg the night before procedures |
187 |
Bismuth Subnitrate, Iodoform and Liquid Paraffin Paste |
R01AX30984G6001XX |
B |
As a mild antiseptic for wounds and abscesses. Sterile gauze impregnated with paste for packing cavities after otorhinological surgery |
|
As directed for local application |
188 |
Bisoprolol Fumarate 2.5 mg Tablet |
C07AB07-000-T10-01-XXX |
B |
i) Hypertension
ii)Coronary heart disease (angina pectoris)
iii) Treatment of stable congestive cardiac failure in addition to ACEI's and diuretics |
|
1.25 mg once daily, gradually titrate to maximum tolerable dose
(i) & (ii): Max: 20mg/ day
(iii): Max 10mg/ day
|
189 |
Bisoprolol Fumarate 5 mg Tablet |
C07AB07-000-T10-02-XXX |
B |
i) Hypertension
ii)Coronary heart disease (angina pectoris)
iii) Treatment of stable congestive cardiac failure in addition to ACEI's and diuretics |
|
1.25 mg once daily, gradually titrate to maximum tolerable dose
(i) & (ii): Max: 20mg/ day
(iii): Max 10mg/ day |
190 |
Bleomycin 15 mg Injection |
L01DC01110P4001XX |
A |
Solid tumours; Lymphomas |
|
15 - 30 mg weekly in divided doses or 10 - 20 mg/m2 once or twice weekly or 10 mg/m2 slow bolus in 15 minutes D1 and D15. Total dosage:should not exceed 300 mg. CHILD: 10 - 15 mg/m2 over 6 hours every 3 - 4 weeks (Routes: SC, IM, IV (either as bolus or as infusion over 24 hours), intra-arterial, intra-pleural) |
191 |
Bortezomib 3.5 mg Injection |
L01XX32000P3001XX |
A* |
Treatment of multiple myeloma |
|
1.3 mg/m2 bodysurfacearea twice weekly for two weekson days 1, 4, 8, and 11 in a 21-day treatment cycle.
At least 3 days should elapse between consecutive doses of bortezomib. |
192 |
Bosentan 125 mg tablet |
C02KX01-000-T10-01-XXX |
A* |
Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV. |
- |
Initially 62.5 mg bd for 4 weeks, then increase to the maintenance dose of 125 mg bd |
193 |
Brimonidine Tartrate 0.15% Ophthalmic |
S01EA05123D2001XX |
A* |
Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension |
|
1 drop in the affected eye(s) 3 times daily |
194 |
Brinzolamide 1% and Brimonidine tartrate 0.2% ophthalmic suspension |
S01EC54-990-D20-01-XXX |
A* |
Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. |
|
1 drop in the affected eye(s) 2 times daily. |
195 |
Brinzolamide 1% ophthalmic suspension |
S01EC04-000-D20-01-XXX |
A* |
Indicated for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. |
For patients who require carbonic anhydrase inhibitor (CAI) but could not tolerate Dorzolamide. |
1 drop 2 times daily.
Some patients may have a better response with one drop three times a day. The dose should not exceed 1 drop in the affected eye(s) 3 times daily. |
196 |
Bromazepam 3 mg Tablet |
N05BA08000T1002XX |
A |
Anxiety disorders |
|
Adult: Initially, 6-18 mg daily in divided doses. Doses up to 60 mg daily have been used. Elderly: Max initial dose: 3 mg daily |
197 |
Bromhexine HCl 4 mg/2 ml Injection |
R05CB02110P3001XX |
A |
Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport |
- |
4mg SC, IM or IV 2 - 3 times daily (maximum 12mg/day). |
198 |
Bromhexine HCl 4 mg/5 ml Oral Solution |
R05CB02110L1001XX |
B |
Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport |
- |
Adult: 8-16 mg three times daily.
Children:
By body weight: 0.3 mg/kg/day 8 hourly for 7 days, then 0.15 mg/kg/day 8 hourly; or
Based on age: 6-12 years – 4mg three times daily; 2-6 years – 2mg three times daily; Less than 2 years – 1mg three times daily. |
199 |
Bromhexine HCl 8 mg Tablet |
R05CB02110T1001XX |
C |
Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport. |
Medical Assistant in health settings without Medical Officer is allowed to prescribe this medicine for adult use only.
|
Adult: 8-16 mg three times daily.
Children:
By body weight: 0.3 mg/kg/day 8 hourly for 7 days, then 0.15 mg/kg/day 8 hourly; or
Based on age: 6-12 years – 4 mg three times daily; 2-6 years – 2 mg three times daily |
200 |
Bromocriptine Mesilate 2.5 mg Tablet |
G02CB01196T1001XX |
A/KK |
i) Hypogonadism or Galactorrhoea ii) Acromegaly |
|
i) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg daily ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses |
201 |
Budesonide 1 mg/2 ml Nebuliser Solution |
R03BA02000A3002XX |
B |
Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators |
|
ADULT : Initially 1 - 2 mg twice daily. CHILD 3 months - 12 years of age : 500 mcg - 1 mg. Maintenance dose : half of the above doses |
202 |
Budesonide 100 mcg/dose Inhaler |
R03BA02000A2101XX |
B |
Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators |
|
ADULT:200 - 1600 mcg daily in 2-4 divided doses. Maintenance with twice daily dosing. CHILD more than 7 years: 200-800 mcg, 2 - 7 years: 200-400 mcg. To be inhaled in 2 - 4 divided doses. |
203 |
Budesonide 160 mcg and Formoterol 4.5 mcg Inhalation |
R03AKO7-989-A21-01-XXX |
A/KK |
Category of prescriber A/KK:
i) Regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:
- Patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists. or
- Patients already adequately controlled on both inhaled corticosteroids and long- acting beta2-agonists.
ii) As a reliever treatment for mild asthma patients who do not adhere to regular inhaled corticosteroid
Category of prescriber A*:
iii) Treatment of COPD patients with a blood eosinophil count of 300 cells/microliter and more
iv) Treatment of COPD patients with blood eosinophil count of 100 cells/microliter and more with history of repeated exacerbation despite regular treatment with long-acting bronchodilators. |
- |
i) Asthma Maintenance therapy: Adult ≥18 yr 160 mcg to 320 mcg bd. Some patients may require up to a max of 640 mcg bd. Adolescent 12-17 yr 160 mcg to 320 mcg bd. Childn 6-11 yr 160 mcg bd, <6 yr Not recommended.
Maintenance & relief Adult and adolescent ≥12 yr 320 mcg/day either as 160 mcg bd or 320 mcg od either morning or evening. For some patients a maintenance dose of 320 mcg bd may be appropriate. Patients should take 160 mcg additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 960 mcg should be taken on any single occasion. A total daily dose of more than 1280 mcg is not normally needed, however a total daily dose of up to 1920 mcg could be used for a limited period. Patients using more than 1280 mcg daily should seek medical advice, should be reassessed & their maintenance therapy reconsidered.
ii) Asthma reliever-only therapy: 160 mcg as needed, but no more than 960 mcg to be taken on any single occasion.
Children <12 yr: Not recommended
iii & iv) COPD: Adult ≥18 yr 320 mcg bd. |
204 |
Budesonide 200 mcg/dose Inhalation |
R03BA02000A2102XX |
B |
Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators |
|
ADULT: 200-1600 mcg daily in 2-4 divided doses. Maintenance with twice daily dosing. CHILD more than 7 years: 200-800 mcg, 2 - 7 years: 200-400 mcg. To be inhaled in 2-4 divided doses. |
205 |
Budesonide 500 mcg/2 ml Nebuliser Solution |
R03BA02000A3001XX |
B |
Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators |
|
ADULT : Initially 1 - 2 mg twice daily. CHILD 3 months - 12 years of age : 500 mcg - 1 mg. Maintenance dose : half of the above doses |
206 |
Budesonide 64mcg Nasal Spray |
R01AD05000A4103XX |
A/KK |
Seasonal allergic, perennial rhinitis and nasal polyposis |
|
ADULT and CHILD 6 years and older. Rhinitis : 2 spray into each nostril once daily in the morning or 1 spray into each nostril twice daily. Nasal polyps : 2 spray twice daily |
207 |
Bumetanide 0.5 mg/ml Injection |
C03CA02000P3001XX |
A* |
Oedema used in furosemide allergic patient |
|
IV injection: 1 - 2 mg repeated after 20 mins. IV infusion: 2 - 5 mg over 30 - 60 mins |
208 |
Bumetanide 1 mg Tablet |
C03CA02000T1001XX |
A* |
Oedema used in furosemide allergic patient |
|
1 mg in the early evening. Up to 5 mg daily in severe cases |
209 |
Bupivacaine 0.5 % Heavy Injection |
N01BB01110P3003XX |
A |
Used for spinal anaesthesia |
|
ADULT: 2 - 4 ml. Not to exceed 2 mg/kg in a single dose |
210 |
Bupivacaine 0.5 % Injection |
N01BB01110P3002XX |
B |
For peripheral sympathetic nerve and epidural (excluding caudal) anaesthesia and obstetrics anaesthesia |
|
Regional nerve block or epidural block: 15 - 30 ml. Nerve block of finger or toe: 2 - 6 ml. Maximum: 2 mg/kg body weight in any 4 hours period, equivalent to 25 - 30 ml in adults of average weight |